The polo-like kinases and aurora kinases have various roles in mitosis, and inhibitors of these kinases are being tested in clinical trials. Recent data have shown that extensive crosstalk exists between the polo-like kinase and aurora kinase pathways, which might affect the efficacy of these drugs. This Review discusses the biology of these kinases and how drugs that inhibit them might be used in the clinic.
- Susanne M. A. Lens
- Emile E. Voest
- René H. Medema
